Reduction of Oxidative Stress in Chronic Kidney Disease Does Not Increase Circulating [alpha]-Klotho Concentrations

Citation metadata

From: PLoS ONE(Vol. 11, Issue 1)
Publisher: Public Library of Science
Document Type: Report
Length: 4,202 words
Lexile Measure: 1480L

Document controls

Main content

Abstract :

The CKD-associated decline in soluble [alpha]-Klotho levels is considered detrimental. Some in vitro and in vivo animal studies have shown that anti-oxidant therapy can upregulate the expression of [alpha]-Klotho in the kidney. We examined the effect of anti-oxidant therapy on [alpha]-Klotho concentrations in a clinical cohort with mild tot moderate chronic kidney disease (CKD). We performed a post-hoc analysis of a prospective randomized trial involving 62 patients with mild to moderate CKD (the ATIC study), all using an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for 12 months. On top of that, the intervention group received anti-oxidative therapy consisting of the combination of pravastatin (40 mg/d) and vitamin E ([alpha]-tocopherol acetate, 300 mg/d) while the placebo was not treated with anti-oxidants. [alpha]-Klotho concentrations were measured at baseline and after 12 months of anti-oxidant therapy. Data were analysed using T-tests and Generalized Estimating Equations, adjusting for potential confounders such as vitamin D, parathyroid hormone, fibroblast-growth-factor 23 (FGF23) and eGFR. The cohort existed of 62 patients with an eGFR (MDRD) of 35 ± 14 ml/min/1.72m.sup.2, 34 were male and mean age was 53.0 ± 12.5 years old. Anti-oxidative therapy did successfully reduce oxLDL and LDL concentrations (P

Source Citation

Source Citation   

Gale Document Number: GALE|A441335198